This report analyzes the worldwide markets for Asthma Therapeutics in US$ Million. The major therapeutic segments analyzed are Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, and Anti- leukotrienes. The report provides separate comprehensive analytics for the USA, Canada, Japan, Europe and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 70 companies including many key and niche players worldwide such as Abbott Laboratories, ALTANA Pharma AG, AstraZeneca, Boehringer Ingelheim, Genentech, Inc., GlaxoSmithKline, Merck & Co., Inc., Novartis Pharma AG, Pfizer Inc., Schering-Plough Corporation and 3M. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.'br.'ébr.

ASTHMA THERAPEUTICS								MCP-1566
A GLOBAL STRATEGIC BUSINESS REPORT


                                             CONTENTS


  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

      Study Reliability And Reporting Limitations                       I-1
      Disclaimers                                                       I-2
      Data Interpretation & Reporting Level                             I-2
       Quantitative Techniques & Analytics                              I-3
      Product Definitions And Scope Of Study                            I-3
       Inhaled Corticosteroids:                                         I-3
       Beta-2 Adrenoreceptor Agonists                                   I-4
       Combinations                                                     I-4
       Anti- leukotrienes                                               I-4
       Others                                                           I-4
        Antihistamines                                                  I-4
        Methylxanthines                                                 I-4
        Mast Cell Stabilizers                                           I-5
        Monoclonal Antibodies                                           I-5
        Anticholinergics                                                I-5


 II. EXECUTIVE SUMMARY

  1. Market Overview                                                    II-1
      Current & Future Analysis                                         II-1
      Competitive Outlook                                               II-1
       Major Asthma Therapeutics by Class                               II-2
       Facts about Asthma                                               II-2

  2. Trends & Issues                                                    II-3
      Combination Drugs - Rule the World                                II-3
      Novel Compounds To Pep Up Growth                                  II-3
      Rise in Pediatric Asthma To Keep Market Lucrative                 II-3
      Toxic Nature of Asthma Drugs - A Serious Concern                  II-3
      Life Threatening Drugs Under Regulatory Scan                      II-3

  3. Product Overview                                                   II-4
      Causes of Asthma                                                  II-4
       Allergens                                                        II-4
       Irritants                                                        II-4
       Other Factors                                                    II-4
      Classes in Asthma                                                 II-5
       A. Mild Intermittent Asthma:                                     II-5
       B. Mild Persistent Asthma:                                       II-5
       C. Moderate Persistent Asthma:                                   II-5
       D. Severe Persistent Asthma:                                     II-5
      Asthma Treatments                                                 II-6
       Combination Asthma Medications                                   II-6
       Over-the-Counter Asthma Medications                              II-6
       Immunotherapy (Allergy shots)                                    II-6
       Alternative Therapies                                            II-6
      Asthma Therapeutics                                               II-6
       Corticosteroids                                                  II-7
       Beta-2 Adrenoreceptor Agonists                                   II-7
       Mast Cell Stabilizers                                            II-7
       Monoclonal Antibodies                                            II-7
        Immune System: Natural Defenders                                II-7
        Human Antibodies                                                II-8
        Polyclonal and Monoclonal Antibodies                            II-8
       Leukotriene Inhibitors                                           II-8
       Methylxanthines:                                                 II-8
       Combination Therapeutics:                                        II-8
      Off Label Therapeutics:                                           II-8
       Anticholinergics:                                                II-8
       Antihistamines:                                                  II-9
      Asthma Therapeutics by Various Classes                            II-9

  4. Product Launches/Innovations                                       II-10
      Future to Witness A Novel Therapeutic in Asthma  Treatment        II-10
      Dr. Reddy's Releases Doxobid in India                             II-10
      Novartis Files Approval for Xolair to Enter Japanese  Market      II-10
      AstraZeneca Receives Approval for Symbicort                       II-10
      GSK Alters Labels for Two Asthma Drugs                            II-10
      DMI BioSciences Starts Evaluating DMI 8393                        II-11
      Inflazyme Begins Phase IIb Trial for IPL512,602                   II-11
      Neurim Develops A Neuroprotective Compound                        II-11
      Xolair Forays into UK                                            II-11
      Critical Therapeutics Rolls Out ZYFLO                            II-11
      Ivax Corp. Introduces Qvar EasiBreathe Inhaler                    II-12
      Altana Rolls Out Respiratory Drug, Alvesco in the UK              II-12
      Sepracor Launches XOPENEX HFA                                     II-12
      Polyphor Commences Research for Protease Inhibitors               II-12
      Novartis Plans to Apply for A New Drug Approval                   II-12
      Asmanex Twisthaler 220 mcg Receives US FDA  Approval              II-12
      GroPep Completes Pre-Clinical Testing of T-Cell  Peptide Drug     II-13
      Able Laboratories Obtains FDA Approval                            II-13
      Acceleration Therapeutics' AT-101 Passes Laboratory  Test         II-13
      Pharmaxis' New Tool to Assess Asthma Passes  Clinical Trial       II-13
      Aventis Seeks FDA Approval Alvesco                               II-13
      Schering-Plough Releases Asmanex Twisthaler                       II-13
      FDA Clears Xolair to Enter US Market                              II-14
      Sepracor Completes Phase III Trial for XOPENEX                    II-14
      Pfizer Conducts Phase II Clinical Studies                         II-14
      Celera and Bayer Plans to End Collaboration                       II-14
      Banyu and Kyorin Starts Distribution of Asthma  Treatment         II-14
      GlaxoSmithKline Introduces Advair                                 II-14
      Novartis Gets FDA Approval for Foradil Aerolizer                  II-14

  5. Recent Industry Activity                                           II-15
      Teva Purchases Ivax                                               II-15
      SkyePharma Strikes A Deal with KOSP                               II-15
      Ranbaxy Inks an In-Licensing Agreement with  Eurodrug             II-15
      Pfizer and Rigel Forms A Collaboration                            II-15
      MAP and Elan Extends Agreement                                    II-15
      Glenmark Collaborates with Teijin Pharma                          II-16
      Pfizer Acquires Meridica                                          II-16
      Bayer and Apax Forms A New Company                                II-16
      KOSP Signs Multiple Agreements                                    II-16
      Novartis Pharma Inks A Licensing Agreement  with Ivax             II-17
      LAB Intends to Purchase Seyvika                                   II-17
      ALTANA and Tanabe Signs A Pact                                    II-17

  6. Focus on Select Players                                            II-18
      Abbott Laboratories (US)                                          II-18
      ALTANA Pharma AG (Germany)                                        II-18
      AstraZeneca (UK)                                                  II-18
      Boehringer Ingelheim (Germany)                                    II-19
      Genentech, Inc. (US)                                              II-19
      GlaxoSmithKline (UK)                                              II-19
      Merck & Co., Inc. (US)                                            II-19
      Novartis Pharma AG (Switzerland)                                  II-19
      Pfizer Inc. (US)                                                  II-20
      Schering-Plough Corporation (US)                                  II-20
      Sepracor Inc. (US)                                                II-20
      The Sanofi-Aventis Group (US)                                     II-21
      3M (US)                                                           II-21

  7. Global Market Perspective                                          II-22
      Table 1: World Recent Past, Current and Future Analysis  for
      Asthma Therapeutics by Geographic Region - US,  Canada, Japan,
      Europe and Rest of World Markets Independently Analyzed by
      Annual Sales for the  Years 2000 through 2010 in US$ Million
      (includes corresponding Graph/Chart)                              II-22

      Table 2: World 10-Year Perspective for Asthma Therapeutics  by
      Geographic Region - Percentage Breakdown of Dollar  Sales for
      US, Canada, Japan, Europe and Rest of World  Markets for the
      Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)    II-22

      Table 3: World Recent Past, Current and Future Analysis  for
      Inhaled Corticosteroids by Geographic Region - US, Canada,
      Japan, Europe and Rest of World Markets Independently Analyzed
      by Annual Sales for the  Years 2000 through 2010 in US$
      Million  (includes corresponding Graph/Chart)                     II-23

      Table 4: World 10-Year Perspective for Inhaled Corticosteroids
      by Geographic Region - Percentage Breakdown of Dollar  Sales
      for US, Canada, Japan, Europe and Rest of World  Markets for
      the Years 2000, 2006 and 2010 (includes corresponding
      Graph/Chart)                                                      II-23

      Table 5: World Recent Past, Current and Future Analysis for
      Short Acting Beta Agonists by Geographic Region - US, Canada,
      Japan, Europe and Rest of World Markets Independently Analyzed
      by Annual Sales for the Years 2000 through 2010 in US$ Million
      (includes corresponding Graph/Chart)                              II-24

      Table 6: World 10-Year Perspective for Short Acting Beta
      Agonists by Geographic Region - Percentage Breakdown of Dollar
      Sales for US, Canada, Japan, Europe and Rest  of World Markets
      for the Years 2000, 2006 and 2010  (includes corresponding
      Graph/Chart)                                                      II-24

      Table 7: World Recent Past, Current and Future Analysis for
      Long Acting Beta Agonists by Geographic Region - US, Canada,
      Japan, Europe and Rest of World Markets Independently Analyzed
      by Annual Sales for the Years 2000 through 2010  in US$
      Million (includes corresponding Graph/Chart)                      II-25

      Table 8: World 10-Year Perspective for Long Acting Beta
      Agonists by Geographic Region - Percentage Breakdown  of
      Dollar Sales for US, Canada, Japan, Europe and Rest  of World
      Markets for the Years 2000, 2006 and 2010  (includes
      corresponding Graph/Chart)                                        II-25

      Table 9: World Recent Past, Current and Future Analysis for
      Combinations by Geographic Region - US, Canada, Japan, Europe
      and Rest of World Markets Independently Analyzed  by Annual
      Sales for the Years 2000 through 2010 in US$  Million
      (includes corresponding Graph/Chart)                              II-26

      Table 10: World 10-Year Perspective for Combinations by
      Geographic Region - Percentage Breakdown of Dollar Sales for
      US, Canada, Japan, Europe and Rest of World Markets for the
      Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)    II-26

      Table 11: World Recent Past, Current and Future Analysis for
      Anti-Leukotrienes by Geographic Region - US, Canada, Japan,
      Europe and Rest of World Markets Independently Analyzed by
      Annual Sales for the Years 2000 through 2010 in US$  Million
      (includes corresponding Graph/Chart)                              II-27

      Table 12: World 10-Year Perspective for Anti-Leukotrienes by
      Geographic Region - Percentage Breakdown of Dollar  Sales for
      US, Canada, Japan, Europe and Rest of World  Markets for the
      Years 2000, 2006 and 2010  (includes corresponding
      Graph/Chart)                                                      II-27

      Table 13: World Recent Past, Current and Future Analysis for
      Other Asthma Therapeutics by Geographic Region - US, Canada,
      Japan, Europe and Rest of World Markets Independently Analyzed
      by Annual Sales for the Years 2000 through 2010 in US$ Million
      (includes corresponding Graph/Chart)                              II-28

      Table 14: World 10-Year Perspective for Other Asthma
      Therapeutics by Geographic Region - Percentage Breakdown  of
      Dollar Sales for US, Canada, Japan, Europe and Rest  of World
      Markets for the Years 2000, 2006 and 2010  (includes
      corresponding Graph/Chart)                                        II-28


III. MARKET

  1. The United States                                                  III-1
      A.Market Analysis                                                 III-1
        Current & Future Analysis                                       III-1
        Asthma Reflections in the US                                    III-1
        Competitive Scenario                                            III-1
         Table 15: Leading Anticholinergic Companies in  the US
         (2006): Percentage Breakdown of Market  Share for
         Boehringer Ingelheim, Dey Inc,  Alpharma and Others
         (includes  corresponding Graph/Chart)                          III-1
        Product Launches/Innovations                                    III-2
        Strategic Developments                                          III-4
        Focus on Key Players                                            III-5
         3M                                                             III-5
         Abbott Laboratories                                            III-5
         Genentech, Inc.                                                III-5
         Merck & Co., Inc.                                              III-6
         Pfizer Inc.                                                    III-6
         Schering-Plough Corporation                                    III-6
         Sepracor Inc.                                                  III-6
         The Sanofi-Aventis Group                                       III-7
      B.Market Analytics                                                III-8
        Table 16: US Recent Past, Current and Future Analysis  for
        Asthma Therapeutics by Product Segment - Inhaled
        corticosteroids, Short acting beta agonists, Long  acting
        beta agonists, Combinations, Anti- leukotrienes  and Other
        Asthma Therapeutics Markets Independently Analyzed by Annual
        Sales for the Years 2000  through 2010 in US$ Million
        (includes  corresponding Graph/Chart)                           III-8

        Table 17: US 10-Year Perspective for Asthma Therapeutics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Inhaled corticosteroids, Short acting beta  agonists, Long
        acting beta agonists, Combinations,  Anti- leukotrienes and
        Other Asthma Therapeutics  Markets for the Years 2000, 2006
        and 2010  (includes corresponding Graph/Chart)                  III-9

  2. Canada                                                             III-10
      A.Market Analysis                                                 III-10
        Current & Future Analysis                                       III-10
        Product Launches/Innovations                                    III-10
        Strategic Development                                           III-10
      B.Market Analytics                                                III-11
        Table 18: Canadian Recent Past, Current and Future Analysis
        for Asthma Therapeutics by Product Segment - Inhaled
        corticosteroids, Short acting beta agonists, Long acting
        beta agonists, Combinations, Anti- leukotrienes  and Other
        Asthma Therapeutics Markets Independently Analyzed by Annual
        Sales for the Years 2000  through 2010 in US$ Million
        (includes  corresponding Graph/Chart)                           III-11

        Table 19: Canadian 10-Year Perspective for Asthma
        Therapeutics by Product Segment - Percentage Breakdown of
        Dollar Sales for Inhaled corticosteroids, Short acting  beta
        agonists, Long acting beta agonists, Combinations, Anti-
        leukotrienes and Other Asthma Therapeutics  Markets for the
        Years 2000, 2006 and 2010  (includes corresponding
        Graph/Chart)                                                    III-12

  3. Japan                                                              III-13
      A.Market Analysis                                                 III-13
        Current & Future Analysis                                       III-13
        Product Approvals/Launches                                      III-13
        Strategic Developments                                          III-13
      B.Market Analytics                                                III-14
        Table 20: Japanese Recent Past, Current and Future Analysis
        for Asthma Therapeutics by Product Segment - Inhaled
        corticosteroids, Short acting beta agonists, Long acting
        beta agonists, Combinations, Anti- leukotrienes and Other
        Asthma Therapeutics Markets IndependentlyAnalyzed by Annual
        Sales for the Years 2000 through 2010 in  US$ Million
        (includes corresponding Graph/Chart)                            III-14

        Table 21: Japanese 10-Year Perspective for Asthma
        Therapeutics by Product Segment - Percentage Breakdown of
        Dollar Sales for Inhaled corticosteroids, Short acting  beta
        agonists, Long acting beta agonists, Combinations, Anti-
        leukotrienes and Other Asthma Therapeutics  Markets for the
        Years 2000, 2006 and 2010  (includes corresponding
        Graph/Chart)                                                    III-15

  4. Europe                                                             III-16
       Market Analysis                                                  III-16
        Current & Future Analysis                                       III-16
        Table 22: European Recent Past, Current and Future Analysis
        for Asthma Therapeutics by Geographic Region - France,
        Germany, UK, Italy, Spain and Rest of Europe Independently
        Analyzed by Annual Sales for the  Years 2000 through 2010 in
        US$ Million  (includes corresponding Graph/Chart)               III-16

        Table 23: European Recent Past, Current and Future Analysis
        for Asthma Therapeutics by Product Segment - Inhaled
        corticosteroids, Short acting beta agonists, Long acting
        beta agonists, Combinations, Anti- leukotrienes and Other
        Asthma Therapeutics Markets Independently Analyzed by Annual
        Sales for the Years 2000 through 2010 in  US$ Million
        (includes corresponding Graph/Chart)                            III-17

        Table 24: European 10-Year Perspective for Asthma
        Therapeutics by Geographic Region - Percentage Breakdown of
        Dollar Sales for France, Germany, UK, Italy, Spain and Rest
        of Europe for the Years 2000, 2006  and 2010 (includes
        corresponding Graph/Chart)                                      III-18

        Table 25: European 10-Year Perspective for Asthma
        Therapeutics by Product Segment - Percentage Breakdown of
        Dollar Sales for Inhaled corticosteroids, Short acting  beta
        agonists, Long acting beta agonists, Combinations, Anti-
        leukotrienes and Other Asthma Therapeutics  Markets for the
        Years 2000, 2006 and 2010  (includes corresponding
        Graph/Chart)                                                    III-19

  4a. France                                                            III-20
       Market Analysis                                                  III-20
        Current & Future Analysis                                       III-20
        Table 26: French Recent Past, Current and Future Analysis
        for Asthma Therapeutics by Product Segment - Inhaled
        corticosteroids, Short acting beta agonists, Long acting
        beta agonists, Combinations, Anti- leukotrienes and Other
        Asthma Therapeutics Markets Independently Analyzed by Annual
        Sales for the Years 2000 through 2010 in US$ Million
        (includes corresponding Graph/Chart)                            III-20

        Table 27: French 10-Year Perspective for Asthma Therapeutics
        by Product Segment - Percentage Breakdown of Dollar Sales
        for Inhaled corticosteroids, Short acting  beta agonists,
        Long acting beta agonists, Combinations, Anti- leukotrienes
        and Other Asthma Therapeutics  Markets for the Years 2000,
        2006 and 2010  (includes corresponding Graph/Chart)             III-21

  4b. Germany                                                           III-22
      A.Market Analysis                                                 III-22
        Current & Future Analysis                                       III-22
        Product Launches/Innovations                                    III-22
        Focus on Key Players                                            III-22
         ALTANA Pharma AG                                               III-22
         Boehringer Ingelheim                                           III-22
      B.Market Analytics                                                III-23
        Table 28: German Recent Past, Current and Future  Analysis
        for Asthma Therapeutics by Product Segment - Inhaled
        corticosteroids, Short acting beta agonists,  Long acting
        beta agonists, Combinations, Anti-  leukotrienes and Other
        Asthma Therapeutics Markets Independently Analyzed by Annual
        Sales for the  Years 2000 through 2010 in US$ Million
        (includes corresponding Graph/Chart)                            III-23

        Table 29: German 10-Year Perspective for Asthma Therapeutics
        by Product Segment - Percentage Breakdown of Dollar Sales
        for Inhaled corticosteroids, Short acting  beta agonists,
        Long acting beta agonists, Combinations, Anti- leukotrienes
        and Other Asthma Therapeutics  Markets for the Years 2000,
        2006 and 2010  (includes corresponding Graph/Chart)             III-24

  4c. The United Kingdom                                                III-25
      A.Market Analysis                                                 III-25
        Current & Future Analysis                                       III-25
        Product Launches/Innovations                                    III-25
        Strategic Developments                                          III-26
        Focus on Key Players                                            III-26
         AstraZeneca                                                    III-26
         GlaxoSmithKline                                                III-26
      B.Market Analytics                                                III-27
        Table 30: UK Recent Past, Current and Future Analysis  for
        Asthma Therapeutics by Product Segment - Inhaled
        corticosteroids, Short acting beta agonists, Long acting
        beta agonists, Combinations, Anti- leukotrienes and Other
        Asthma Therapeutics Markets Independently Analyzed by Annual
        Sales for the Years 2000 through 2010 in US$ Million
        (includes corresponding Graph/Chart)                            III-27

        Table 31: UK 10-Year Perspective for Asthma Therapeutics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Inhaled corticosteroids, Short acting beta  agonists, Long
        acting beta agonists, Combinations,  Anti- leukotrienes and
        Other Asthma Therapeutics  Markets for the Years 2000, 2006
        and 2010  (includes corresponding Graph/Chart)                  III-28

  4d. Italy                                                             III-29
       Market Analysis                                                  III-29
        Current & Future Analysis                                       III-29
        Table 32: Italian Recent Past, Current and Future Analysis
        for Asthma Therapeutics by Product Segment - Inhaled
        corticosteroids, Short acting beta agonists, Long acting
        beta agonists, Combinations, Anti- leukotrienes  and Other
        Asthma Therapeutics Markets Independently Analyzed by Annual
        Sales for the Years 2000  through 2010 in US$ Million
        (includes  corresponding Graph/Chart)                           III-29

        Table 33: Italian 10-Year Perspective for Asthma
        Therapeutics by Product Segment - Percentage Breakdown of
        Dollar Sales for Inhaled corticosteroids, Short acting  beta
        agonists, Long acting beta agonists, Combinations, Anti-
        leukotrienes and Other Asthma Therapeutics  Markets for the
        Years 2000, 2006 and 2010  (includes corresponding
        Graph/Chart)                                                    III-30

  4e. Spain                                                             III-31
       Market Analysis                                                  III-31
        Current & Future Analysis                                       III-31
        Table 34: Spanish Recent Past, Current and Future  Analysis
        for Asthma Therapeutics by Product Segment - Inhaled
        corticosteroids, Short acting beta agonists, Long acting
        beta agonists, Combinations, Anti- leukotrienes  and Other
        Asthma Therapeutics Markets Independently Analyzed by Annual
        Sales for the Years 2000  through 2010 in US$ Million
        (includes  corresponding Graph/Chart)                           III-31

        Table 35: Spanish 10-Year Perspective for Asthma
        Therapeutics by Product Segment - Percentage Breakdown of
        Dollar Sales for Inhaled corticosteroids, Short acting  beta
        agonists, Long acting beta agonists, Combinations, Anti-
        leukotrienes and Other Asthma Therapeutics  Markets for the
        Years 2000, 2006 and 2010  (includes corresponding
        Graph/Chart)                                                    III-32

  4f. Rest of Europe                                                    III-33
      A.Market Analysis                                                 III-33
        Current & Future Analysis                                       III-33
        Product Approvals/Launches                                      III-33
        Strategic Development                                           III-34
        Focus on Select Player                                          III-34
         Novartis Pharma AG (Switzerland)                               III-34
      B.Market Analytics                                                III-35
        Table 36: Rest of Europe Recent Past, Current and Future
        Analysis for Asthma Therapeutics by Product Segment -
        Inhaled corticosteroids, Short acting beta agonists,  Long
        acting beta agonists, Combinations, Anti-  leukotrienes and
        Other Asthma Therapeutics Markets Independently Analyzed by
        Annual Sales for the  Years 2000 through 2010 in US$ Million
        (includes corresponding Graph/Chart)                            III-35

        Table 37: Rest of Europe 10-Year Perspective for Asthma
        Therapeutics by Product Segment - Percentage  Breakdown of
        Dollar Sales for Inhaled corticosteroids, Short acting beta
        agonists, Long acting beta agonists, Combinations, Anti-
        leukotrienes and Other Asthma Therapeutics Markets for the
        Years 2000, 2006 and 2010 (includes corresponding
        Graph/Chart)                                                    III-36

  5. Rest of World                                                      III-37
      A.Market Analysis                                                 III-37
        Current & Future Analysis                                       III-37
        Product Launches                                                III-37
        Strategic Developments                                          III-37
      B.Market Analytics                                                III-38
        Table 38: Rest of World Recent Past, Current and Future
        Analysis for Asthma Therapeutics by Product Segment -
        Inhaled corticosteroids, Short acting beta agonists, Long
        acting beta agonists, Combinations, Anti- leukotrienes and
        Other Asthma Therapeutics Markets Independently Analyzed by
        Annual Sales for the Years 2000 through 2010 in  US$ Million
        (includes corresponding Graph/Chart)                            III-38

        Table 39: Rest of World 10-Year Perspective for Asthma
        Therapeutics by Product Segment - Percentage Breakdown of
        Dollar Sales for Inhaled corticosteroids, Short acting  beta
        agonists, Long acting beta agonists, Combinations, Anti-
        leukotrienes and Other Asthma Therapeutics  Markets for the
        Years 2000, 2006 and 2010  (includes corresponding
        Graph/Chart)                                                    III-39


 IV. COMPETITIVE LANDSCAPE